Peptide questions · Enicepatide
How long does enicepatide take to work?
Reviewed Evidence: ModeratePublished by PepVault
Enicepatide’s onset is days–2 weeks, its peak effect comes at 48 weeks (phase 2 endpoint, no plateau), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 1 (Chakravarthy 2026, Mol Metab; NCT04838405), obesity phase 2 (Roche, Jan-27-2026; ADA 2026 poster; NCT06525935), diabetes phase 2 (Roche, Sep-22-2026; NCT06628362), ENITH records on ClinicalTrials.gov. Investigational.
Enicepatide week by week
The library places five of its research notes on enicepatide on the days they cover, from day 1 to day 336 and on: 4 on randomized trials and 1 on clinical data.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–28 (weeks 1–4) | Two milligrams, the first step | Randomized trial |
| Days 29–112 (weeks 5–16) | Through the middle steps | Randomized trial |
| Days 85–336 (weeks 13–48) | With type 2 diabetes | Randomized trial |
| Days 113–336 (weeks 17–48) | The top dose tested | Randomized trial |
| From day 337 on | A long-term medicine, not a course | Clinical data |

Model. Individual results vary.
The enicepatide timeline’s milestones
The library’s timeline for enicepatide marks 4 points from week 1 to week 48, backed by moderate evidence overall.
- Week 1: Commonly reported: appetite dropping in the first days, with nausea most likely early in each step
- Week 4: Phase 1: about 5% to 8% average loss after 4 weekly doses vs 0.5% on placebo
- Week 27: The obesity phase 2 trial reached each group's top dose by about week 27
- Week 48: Obesity phase 2 endpoint: about 22.5% more loss than placebo at 24 mg, not yet levelling off
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why enicepatide takes that long
Enicepatide’s half-life is about 5.5 days (132 hours), so one dose is about 96.9% cleared after 28 days.
On its schedule (Weekly) the doses overlap, and the level of enicepatide keeps climbing for about 22–28 days before it levels off, so the first 22–28 days run below the level the later weeks hold.
The notes on enicepatide follow the trials’ dose steps, 2mg, 8mg and 24mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Enicepatide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, enicepatide among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does enicepatide take to work?
Enicepatide’s onset is days–2 weeks, its peak effect comes at 48 weeks (phase 2 endpoint, no plateau), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does enicepatide reach its peak effect?
By the library’s timeline, enicepatide’s peak effect comes at 48 weeks (phase 2 endpoint, no plateau), backed by moderate evidence.
How long is enicepatide usually run?
The library’s timeline gives enicepatide’s typical duration as ongoing; its cycle note says: Used continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks.
What does the library say about the first days on enicepatide?
Its first note on enicepatide, for days 1–28 (weeks 1–4), is “Two milligrams, the first step”, resting on randomized trials.